a day ago
Block Trades Boost Jubilant Stocks: Ingrevia Soars 11%, FoodWorks Up 2.5%
Last Updated:
Jubilant Block Deal: Shares of Jubilant Group companies rallied on June 13 following large block deals
Jubilant Block Deal: Shares of Jubilant Group companies rallied on June 13 following large block deals, with market participants attributing the trades to promoter stake sales aimed at funding the group's upcoming acquisition of a strategic stake in Hindustan Coca-Cola Beverages (HCCB).
Jubilant FoodWorks rose 2.5% on the NSE, while Jubilant Ingrevia surged over 11% as significant chunks of equity changed hands via block trades. According to exchange data, five block deals involving 1.06 crore shares — or 1.6% of Jubilant FoodWorks' equity — were executed. Meanwhile, six block trades in Jubilant Ingrevia saw 98.7 lakh shares (6.2% equity) change hands.
In addition, Jubilant Pharmova witnessed a single block trade comprising 48 lakh shares, amounting to roughly 3% of its equity.
The cumulative value of the block transactions across the three companies is estimated at Rs 1,896 crore, as per market sources.
According to reports, the Bhartia family — promoters of the Jubilant Group — likely offloaded these stakes to partially fund their earlier-announced Rs 12,500 crore investment in Hindustan Coca-Cola Holdings (HCCH). In December, the group said it would acquire a 40% stake in HCCH via its subsidiary, Jubilant Beverages Ltd. HCCH is the parent company of HCCB, India's largest bottler for Coca-Cola.
Jubilant FoodWorks operates the Domino's Pizza franchise across India, Nepal, Sri Lanka, and Bangladesh. It also manages Dunkin', Popeyes, and homegrown brands like Ekdum! and Hong's Kitchen. As of June 13, its market cap stood at around Rs 45,000 crore.
Jubilant Pharmova, the group's pharma and life sciences arm, focuses on sterile injectables, contract research, allergy therapy, and radiopharmaceuticals. Its market capitalisation was Rs 17,760 crore.
Jubilant Ingrevia operates in the life sciences and specialty chemicals segment, manufacturing products such as vitamin B3 and B4, pyridine derivatives, and ethanol. It also provides CDMO (contract development and manufacturing) services, with a market cap of nearly Rs 12,000 crore.
First Published:
